Article Sidebar
Views pdf: 118
SUPERSELECTIVE TRANSARTERIAL CHEMOEMBOLIZATION USING DRUG ELUTING BEAD DC BEAD M1 FOR PREOPERATIVE TREATMENT OF EARLY-STAGE HEPATOCELLULAR CARCINOMA: A CASE REPORT
Main Article Content
Abstract
Objective: To evaluate the role of superselective transarterial chemoembolization (TACE) in the initial management of early-stage hepatocellular carcinoma (HCC) with high risk of postoperative recurrence, aiming to optimize curative treatment outcomes. Methods: We report a clinical case of a 50-year-old female with a history of chronic hepatitis B, diagnosed with early-stage HCC characterized by a hypervascular tumor and markedly elevated tumor markers (AFP >1660 IU/mL, PIVKA-II = 2831 mAU/mL). The patient underwent superselective drug-eluting bead TACE (DEB-TACE) using DC Bead M1 loaded with doxorubicin. One month later, she underwent curative liver resection and was followed for 9 months postoperatively. Results: Post DEB-TACE imaging demonstrated complete tumor necrosis, with a significant reduction in AFP and PIVKA-II levels. Histopathological examination confirmed total tumor necrosis with no viable malignant cells. At 9-month follow-up, no recurrence was observed and liver function remained preserved. Conclusion: Superselective DEB-TACE may be an effective preoperative strategy in early-stage HCC patients with high-risk features for recurrence, contributing to improved curative resection rates and short-term prognosis.
Article Details
Keywords
Hepatocellular carcinoma, superselective transarterial chemoembolization
References
2. Cai Y., Xie K., Adeeb Alhmoud M. N., et al. (2023). Effect of PIVKA-II and AFP secretion status on early recurrence of hepatocellular carcinoma after open and laparoscopic surgery. Cancer Med, 12(17): 17866-17877.
3. Aliberti C., Carandina R., Lonardi S., et al. (2017). Transarterial Chemoembolization with Small Drug-Eluting Beads in Patients with Hepatocellular Carcinoma: Experience from a Cohort of 421 Patients at an Italian Center. J Vasc Interv Radiol, 28(11): 1495-1502.
4. Abdelhamed W., El-Kassas M. (2023). Hepatocellular carcinoma recurrence: Predictors and management. Liver Research, 7(4): 321-332.
5. Yasuda S., Matsuo Y., Doi S., et al. (2024). Preoperative predictors of very early recurrence in patients with hepatocellular carcinoma beyond the Milan criteria. Langenbecks Arch Surg, 409(1): 283.
6. Ma X. L., Zhu J., Wu J., et al. (2018). Significance of PIVKA-II levels for predicting microvascular invasion and tumor cell proliferation in Chinese patients with hepatitis B virus-associated hepatocellular carcinoma. Oncol Lett, 15(6): 8396-8404.
7. Reig M., Forner A., Rimola J., et al. (2022). BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update. J Hepatol, 76(3): 681-693.
8. Guo C., Zou X., Hong Z., et al. (2021). Preoperative transarterial chemoembolization for barcelona clinic liver cancer stage A/B hepatocellular carcinoma beyond the milan criteria: a propensity score matching analysis. HPB (Oxford), 23(9): 1427-1438.
9. Hsu K.-F., Chu C.-H., Chan D.-C., et al. (2012). Superselective transarterial chemoembolization vs hepatic resection for resectable early-stage hepatocellular carcinoma in patients with Child-Pugh class a liver function. European Journal of Radiology, 81(3): 466-471.
10. Yoon J. H., Choi S. K. (2023). Management of early-stage hepatocellular carcinoma: challenges and strategies for optimal outcomes. Journal of Liver Cancer, 23(2): 300-315.